The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis
- 7 June 2021
- journal article
- review article
- Published by Springer Nature in Neurological Sciences
- Vol. 42 (8) , 3093-3099
Abstract
Background The prevalence of COVID-19 is different in studies conducted in different countries. The aim of this systematic review and meta-analysis is to estimate the pooled prevalence of COVID-19 in patients with MS. Methods Two independent researchers independently searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021. The search strategy included the MeSH and text words as (((coronavirus OR Wuhan coronavirus OR novel coronavirus OR coronavirus disease OR COVID-19 OR 2019 novel coronavirus infection OR 2019-nCOV OR severe acute respiratory syndrome coronavirus 2 OR SARS-CoV-2) AND (Multiple Sclerosis OR Sclerosis, Multiple) OR Sclerosis, Disseminated) OR Disseminated Sclerosis) OR MS (Multiple Sclerosis)) OR Multiple Sclerosis, Acute Fulminating). Results We found 1466 articles by literature search, and after deleting duplicates, 1029 remained. Twelve articles remained for meta-analysis. Totally, 101,462 patients were evaluated and the total number of possible/confirmed cases was 1394. Mean age ranged from 35 to 54 years. Totally, 49 patients died. The pooled prevalence of suspected COVID-19 in MS patients was 4% (95% CI: 3–4%) (I2 = 98.5%, P < 0.001). The pooled prevalence of hospitalization in infected cases was 10% (95% CI: 7–12%) (I2 = 95.6%, P < 0.001). The pooled prevalence of death in hospitalized cases was 4% (95% CI: 1–6%) (I2 = 82.4%, P < 0.001). Conclusion Hospitalization rate is higher among MS patients based on COVID-19 infection while the pooled infection rate is estimated as 4%.Keywords
This publication has 30 references indexed in Scilit:
- B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in IranMultiple Sclerosis and Related Disorders, 2020
- Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from IranMultiple Sclerosis and Related Disorders, 2020
- Real estimates of mortality following COVID-19 infectionThe Lancet Infectious Diseases, 2020
- An Italian programme for COVID-19 infection in multiple sclerosisThe Lancet Neurology, 2020
- The COVID-19 pandemic and the use of MS disease-modifying therapiesMultiple Sclerosis and Related Disorders, 2020
- Estimating case fatality rates of COVID-19The Lancet Infectious Diseases, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-AnalysisPLOS ONE, 2016
- SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferonCurrent Opinion in Virology, 2012